
Episode 49
Biotech Hangout
00:00
Is It Possible to Be Confident About Anything You Do?
A year ago, the value of efficacy was not as great because the phase 2B study for psoriasis hadn't read out and ticked the BMS compound. So to now known as cetic-2, hadn't gone through its regulatory process. And so what was a significantly lower valuation a year ago became $4 billion, but we went in with a very clear set of parameters. We're just totally excited about this. It's really great for us."
Transcript
Play full episode